Novartis delivers 12% sales and 21% core operating income growth from continuing
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance NovartisNovartis Raises Outlook After…